Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Eur J Neurosci. Author manuscript; available in PMC 2010 August 1.
Published in final edited form as:
PMCID: PMC2758854

Enhanced Dense Core Granule Function and Adrenal Hypersecretion in a Mouse Model of Rett Syndrome

Mecp2 Null Adrenal Dysfunction


Rett Syndrome (RTT) is a progressive developmental disorder resulting from loss of function mutations in the gene encoding MeCP2 (methyl-CpG-binding protein 2), a transcription regulatory protein. The RTT phenotype is complex and includes severe cardiorespiratory abnormalities, dysautonomia and behavioral symptoms of elevated stress. These findings have been attributed to an apparent hyperactivity of the sympathetic nervous system due to defects in brainstem development; however, the possibility that the peripheral sympathoadrenal axis itself is abnormal has not been explored. The present study demonstrates that the adrenal medulla and sympathetic ganglia of Mecp2 null mice exhibit markedly reduced catecholamine content compared to wildtype controls. Despite this, null animals exhibit significantly higher plasma epinephrine levels, suggesting enhanced secretory granule function in adrenal chromaffin cells. Indeed, we find that Mecp2 null chromaffin cells exhibit a cell autonomous hypersecretory phenotype characterized by significant increases in the speed and size of individual secretory granule fusion events in response to electrical stimulation. These findings appear to indicate accelerated formation and enhanced dilation of the secretory granule fusion pore, resulting in elevated catecholamine release. Our data therefore highlight abnormal catecholamine function in the sympathoadrenal axis as a potential source of autonomic dysfunction in RTT. These findings may help to explain the apparent “overactivity” of the sympathetic nervous system reported in RTT patients.

Keywords: exocytosis, chromaffin, sympathetic, neurosecretion, neuroendocrine


Rett Syndrome (RTT) is an X-linked dominant neurodevelopmental disorder that affects approximately 1/10,000 live female births (Van den Veyver and Zoghbi, 2002; Moretti and Zoghbi, 2006). Loss-of-function mutations in the gene encoding methyl-CpG binding protein 2 (MeCP2) account for the vast majority of RTT cases (Amir et al., 1999; Moretti & Zoghbi, 2006), and mice carrying hypomorphic, truncated or null alleles at the Mecp2 locus exhibit RTT-like symptoms (Chen et al., 2001; Guy et al., 2001; Shahbazian et al., 2002; Pelka et al., 2006; Samaco et al., 2008). Classical RTT is characterized by apparently normal postnatal development until 6 to 18 months of life, followed by a marked neurological decline (Hagberg et al., 1983; Shahbazian & Zoghbi, 2002; Vorsanova et al., 2004; Chahrour & Zoghbi, 2007). Initial features of the disease typically include loss of acquired speech and head growth deceleration; subsequently, RTT patients develop severe cognitive and motor deficits as well as disordered and irregular breathing, cardiovascular and gastrointestinal dysautonomia, and behavioral symptoms of elevated stress (Hagberg et al., 1983; Moretti & Zoghbi, 2006).

To date, studies on the pathogenesis RTT have focused primarily on identifying defects in the central neuraxis that may underlie symptoms of the disease. However, the fact that autonomic control is profoundly affected in RTT raises the possibility that the peripheral nervous system is affected as well. Although there is growing clinical evidence of an imbalance between sympathetic and parasympathetic tone in RTT patients, with an apparent “hyperactivity” of the sympathetic nervous system (Julu et al., 2001; Acampa & Guideri, 2006; Acampa et al., 2008), these alterations have been attributed to presumed defects in brainstem maturation (Julu et al., 1997a, b).

Recent studies from our laboratory indicate that loss of MeCP2 results in an abnormal neurosecretory phenotype that affects central and peripheral neurons and adrenal chromaffin cells and is characterized by enhanced transmitter release in vitro (Wang et al., 2006). Based on these findings, we hypothesize that symptoms of autonomic imbalance in RTT could result from elevated secretion of catecholamines from the peripheral sympathoadrenal axis in vivo. Therefore, the present study was designed to define the role of MeCP2 in sympathoadrenal function in vivo as well as mechanisms that underlie enhanced catecholamine exocytosis in Mecp2 null cells. Our findings demonstrate that, despite reduced adrenal catecholamine content, Mecp2 null chromaffin cells exhibit a cell autonomous, hypersecretory phenotype that is characterized by an increase in both the rate and amount of catecholamine exocytosis, and an increase in the number of secretion-ready granules competent for release upon cell stimulation. Furthermore, this hypersecretory phenotype is associated with a significant increase in the plasma level of epinephrine in isoflurane-anesthetized Mecp2 null mice compared to wildtype controls. On the basis of these findings we propose that hypersecretion of epinephrine from the adrenal medulla could explain or contribute to clinical observations of apparent sympathetic hyperactivity in RTT patients.

Materials and Methods


Mecp2 null mice (Chen et al., 2001) were bred from founder animals from the Mutant Mouse Regional Resource Center (University of California, Davis, CA). Animals were studied at post-natal day 35 (P35), an age at which they exhibit marked RTT-like symptoms (Ogier et al., 2007). All experimental procedures were approved by the Institutional Animal Care and Use Committee at Case Western Reserve University.

Adrenal Gland Immunohistochemistry

Animals were euthanized by CO2 asphyxiation. Adrenal glands were removed and fixed in 4% paraformaldehyde at 4°C for 2 hours. Cryoprotection was achieved by immersion in 10%, 15%, 20%, and 30% sucrose solutions over the next two days, after which the glands were embedded in OCT and frozen at −80°C. Sections were cut with a Leica Jung Frigocut 2800N at 16μm and mounted on Fisherbrand Superfrost/Plus microscope slides. Sections were allowed to dry for one hour, and were then washed twice with PBS for 10 minutes. Slides were blocked with a fresh dilution buffer containing 0.02M NaPO4 buffer, 50mM NaCl, 0.3% Triton X-100, and 2% BSA fraction V at room temperature for one hour. Slides were then incubated with primary antibodies against anti-MeCP2 (rabbit, Upstate #07-013) and anti-tyrosine hydroxylase (TH; chicken, Aves #TH) overnight at 4°C. Slides were then washed twice with PBS followed by a single wash with dilution buffer for 10 minutes at room temperature, then incubated with secondary antibodies conjugated to FITC and Cy3 (Goat anti-rabbit FITC (ICN/Cappel #55646), Donkey anti-chicken Cy3 (Jackson #703-166-155)). Immunofluorescence images were captured with a Q-Imaging Retiga EXi Fast1394 monochromatic CCD camera.

Adrenal Gland Morphometry

Animals were euthanized by CO2 asphyxiation at postnatal day 35 (P35) and perfused intracardially with ice-cold PBS followed by 4% paraformaldehyde. Dissected adrenal glands were postfixed and cryoprotected as described above. Glands were serially sectioned at 30 μm and directly imaged without staining. Total gland area as well as cortical and medullary area were measured from every third section of the gland. Volumes (less vascular spaces) were determined by multiplying the measured area by the thickness.

Catecholamine Measurements

HPLC with electrochemical detection was used to determine adrenal gland, superior cervical ganglion (SCG), and plasma concentrations of norepinephrine, epinephrine, and dopamine. Mecp2 null and wildtype animals (P35) were anesthetized with isoflurane (Sigma) and euthanized by blood draw through cardiac puncture. Glutathione (GSH, 3.9mM, Sigma) and ethylene glycol tetraacetic acid (EGTA, 4.7mM, Sigma) were added to blood samples to prevent clotting and catecholamine degradation. Samples were centrifuged at 2000 × g for 10 minutes at 4°C, after which the plasma supernatant was aliquoted and frozen at −80°C. Adrenal glands and SCGs were rapidly dissected and frozen at −80°C. Blood and tissue samples were analyzed by the Neurochemistry Core Lab at Vanderbilt University’s Center for Molecular Neuroscience Research (Nashville, TN) as previously described (Perez & Palmiter, 2005).


Adrenal medullary chromaffin cells were isolated and cultured and perforated patch voltage clamp recordings were performed as previously described (Fulop et al., 2005). Internal pipette solution contained (in mM): 135 Cs-glutamate, 10 HEPES-H, 9.5 NaCl, 0.5 TEA-Cl, and 0.53 amphotericin B, pH adjusted to 7.2, and osmolarity adjusted to 310 mOsm. During recordings, cells were constantly superfused with a Ringer’s solution containing (in mM): 150 NaCl, 10 HEPES-H, 10 glucose, 2.5 CaCl2, 2.8 KCl, and 2 MgCl2, with pH adjusted to 7.2 and osmolarity adjusted to 320 mOsm. Cells were allowed to perforate until the access resistance dropped to below 30 MΩ before recording. All recordings were acquired with an EPC-9 amplifier (HEKA Elekronik, Lambrecht, Germany) under the control of Pulse software (v8.40, HEKA Electronik). To measure the release kinetics and fusion pore dynamics, cells were held at a −80 mV command potential and stimulated with a train of simulated action potentials at 0.5 Hz or 15 Hz in conjunction with amperometric detection of released catecholamines (Chan & Smith, 2001). To assess Readily Releasable Pool (RRP) and the Reserve Pool (RP), cells were depolarized from a resting potential of −80 mV to +10 mV with pulses of increasing duration, allowing 45 seconds in between pulses for the cell to recover (Smith et al., 1998; Voets et al., 1999). Evoked capacitance jumps were measured as previously described (Smith et al., 1998). Briefly, cells were held in the perforated patch configuration and clamped at a holding potential of −80 mV. Cell capacitance was measured in the frequency domain by imposing a 634 Hz sine wave of 20 mV amplitude on the holding potential. These recording conditions were previously shown to accurately measure capacitance changes due to granule fusion independent of fusion mode (Fulop & Smith, 2006).

Electrochemical Recordings

Electrochemical catecholamine detection was performed with commercially available carbon fiber electrodes (ALA Scientific Instruments, Longneck, NY) and fiber tips were always cut fresh before recordings. A +650 mV potential was placed on the fiber tip by a VA-10x dedicated amperometry amplifier with a 1 GΩ head stage (ALA Scientific Instruments). Recordings were filtered with a 1.3 kHz Bessel filter before being sampled at 20 kHz by an ITC-1600 data acquisition system (Instrutech, Port Washington, NY). After data acquisition, amperometric data were analyzed with a macro modified from the Spike protocol (Gomez et al., 2002) written in Igor Pro (WaveMetrics, Lake Oswego, OR).

Statistical Analysis

Data were analyzed by the two-tailed Student’s t-test using the Minitab software package (version 15, Minitab, Inc., State College, PA, USA). All results are presented as the mean ±the standard error of the mean. A statistical significance criterion of α = 0.05 was used for all tests.


MeCP2 protein expression in the mouse adrenal gland

As a first step towards defining the role of MeCP2 in adrenal medullary function, we examined the distribution of MeCP2 protein in wildtype (Mecp2+/y) adrenal glands using immunocytochemical staining. Frozen sections from postnatal day (P)35 mouse glands were double-stained for MeCP2 and the catecholamine-synthesizing enzyme tyrosine hydroxylase (TH) to identify chromaffin cells (Fig. 1A). MeCP2 immunoreactivity was strongly expressed in the nuclei of TH-positive chromaffin cells distributed throughout the adrenal medulla and was also present at lower levels in (TH-negative) cortical cells. The staining exhibited a punctuate pattern characteristic of heterochromatic foci where MeCP2 protein is concentrated (Mullaney et al., 2004) whereas control sections from Mecp2 null mice showed no specific nuclear staining (Fig. 1A).

Figure 1
A) MeCP2 and TH immunostaining in the adrenal gland. The panel to the left shows an adrenal gland section from a wildtype mouse double-stained for MeCP2 (green) and TH (red). Magnification x10. The panel on the right shows the same adrenal section at ...

Adrenal gland morphology in Mecp2 null mice

To establish whether or not loss of MeCP2 alters adrenal gland structure, we performed morphometric analyses of paraformaldehyde-fixed glands from P35 wildtype and Mecp2 null mice. These studies revealed that, in mutants, the overall size of the adrenal tends to be smaller than in wildtypes, however, this difference is not statistically significant (t5 = −1.60, P = 0.17; Fig. 1B). In contrast, the size of the medulla alone (mutant, 0.17±0.02 mm3 vs. wildtype, 0.26±0.03 mm3; t5 = −2.70, P = 0.04), as well as the ratio of the medulla to the whole gland (mutant, 14.1±0.5% vs. wildtype, 16.7±0.8%; t5 = −2.68, P = 0.04), are reduced by 35% and 15%, respectively, compared to wildtype controls (Fig. 1B). These changes could be related in part to reduction in the body weight of mutants compared to wildtypes (mutant, 12.4 ± 3.02 grams vs wildtype, 19.6 ± 1.5 grams). The decrease in medullary tissue volume was not due to decreased vascularity, as blood vessel volume was not significantly different between mutants and wildtypes (mutant, 0.038±0.007 mm3vs. wildtype, 0.067±0.014 mm3; t4 = −1.88, P = 0.13).

Adrenal and sympathetic ganglion catecholamine levels in Mecp2 null mice

We next sought to determine whether or not reduced adrenal medullary tissue volume in mutant animals was associated with parallel changes in adrenal catecholamine content. To minimize the potentially confounding effects of handling stress on adrenal catecholamine levels, animals were pre-handled for three days and then anesthetized with isoflurane during gland removal. These experiments revealed significant decreases in both whole gland catecholamine content (Fig. 2A) and in the tissue concentration of catecholamines in mutant adrenals compared to wildtype controls (% wildtype values: dopamine, 58%, t36 = −4.84, P = 0.00001; norepinephrine, 66%, t36 = −4.80, P = 0.00001; epinephrine, 76%, t31 = −2.61, P = 0.014), without any change in the epinephrine/norepinephrine ratio (wildtype, 1.64; mutant, 1.81; t34 = 1.56, P = 0.13). To determine whether or not these changes are specific to the adrenal gland, we also examined catecholamine content in the sympathetic superior cervical ganglion (SCG). As with the adrenals, dopamine and norepinephrine content in the mutant SCG were significantly decreased compared to wildtype controls (t10 = −4.00, P = 0.003 and t11 = −2.84, P = 0.016, respectively; Fig. 2B). Epinephrine levels are negligible in the SCG and were not different between wildtype and mutant animals (t14 = −0.59, P = 0.57; data not shown).

Figure 2
Tissue and plasma catecholamine levels. A) Catecholamine concentration in adrenal gland tissue from n=20 wildtype (Mecp2+/y) and n=19 mutant (Mecp2−/y) animals. Mutant glands had significantly reduced levels of norepinephrine (NE), epinephrine ...

Plasma catecholamine levels in Mecp2 null mice

At rest, adrenal chromaffin cells primarily secrete epinephrine, and plasma epinephrine levels primarily reflect secretion from the adrenal medulla (Malmejac, 1964). To determine whether or not circulating epinephrine levels in mutants reflected the reduced content in the adrenal medulla, we compared plasma catecholamine content in wildtype and Mecp2 null animals. Plasma samples were obtained under isoflurane anesthesia from the same animals used for adrenal catecholamine measurements. Surprisingly, mutant animals exhibited a nearly three-fold increase in the plasma level of epinephrine (t21 = 3.05, P = 0.006; Fig. 2C) and a two-fold increase in the ratio of epinephrine to norepinephrine (t31 = 2.65, P = 0.013; Fig. 2D) compared to wildtype controls, despite the sharp reduction in adrenal catecholamine content in the same animals. In addition, plasma dopamine levels were significantly increased nearly two-fold compared to wildtypes (t29 = 2.32, P = 0.028; Fig. 2C).

Altered quantal secretion kinetics in isolated Mecp2 null chromaffin cells

Plasma epinephrine levels are elevated in Mecp2 null mice compared to wildtype controls, despite a significant reduction in epinephrine content in the adrenal gland. This finding is consistent with our previous report that Mecp2 null chromaffin cells exhibit enhanced basal and nicotine-evoked catecholamine exocytosis in vitro (Wang et al., 2006). To investigate the voltage-dependent processes that may contribute to enhanced secretory function in Mecp2 null cells, quantal catecholamine release was measured by carbon fiber amperometry. Cells were held at −80 mV in perforated patch voltage clamp and stimulated with action potential equivalent waveforms as previously described (Chan & Smith, 2001). Figure 3A shows representative raw traces for each cell type stimulated at 0.5 Hz, a condition designed to mimic splanchnic input under resting sympathetic tone (Brandt et al., 1976; Kidokoro & Ritchie, 1980). A section of each record is expanded in Figures 3B and 3C and illustrates that, in Mecp2−/y cells, each stimulus is more likely to evoke a secretory event than in wildtype cells. To quantify the periodicity of the secretory behavior in mutant and wildtype cells, we compared the power spectra of amperometric recordings of each genotype. These spectra revealed that Mecp2−/y cells exhibited a higher amplitude signal at the 0.5 Hz stimulus frequency than in wildtype cells (Fig. 3C.ii). Thus we conclude that the Mecp2−/y chromaffin cells exhibit tighter stimulus-secretion coupling.

Figure 3
Increased stimulus-secretion coupling in Mecp2 null mice. A) Typical amperometric recordings from a wildtype (Mecp2+/y) and mutant (Mecp2−/y) adrenal chromaffin cell stimulated with a 0.5Hz train of action potential equivalents (APe). B) An expansion ...

To further characterize the mechanisms underlying the mutant secretory phenotype, we analyzed individual amperometric spikes, representing single granule fusion events, with respect to spike amplitude, slope, half-width, and total charge (Fig. 4). Cells were again stimulated at 0.5 Hz and 15 Hz to mimic physiologic sympathetic firing patterns of basal sympathetic tone and acute sympathetic activation, respectively (Brandt et al., 1976; Kidokoro & Ritchie, 1980; Fulop et al., 2005). At 0.5 Hz, stimulation evokes exocytosis through a restricted secretory fusion pore in which catecholamine release is limited and quantal size is reduced compared to full collapse exocytosis (Fulop et al., 2005). In contrast, at 15 Hz, the secretory fusion pore dilates rapidly and does not act to limit the rate of catecholamine exocytosis (Fulop et al., 2005); therefore, the mean spike charge at 15 Hz provides a measure of maximal granule catecholamine release. Thus, comparison of amperometric spike characteristics evoked at both frequencies can provide additional information about granule fusion behavior and modulation of fusion pore dilation and thus catecholamine release (Sugita, 2008).

Figure 4
Comparison of Mecp2 null and wildtype spike parameters. A) Schematic of an amperometric spike illustrating the parameters used for analysis. Spike amplitude (Iamp) is measured as the height of the spike from baseline. Spike charge is determined by integrating ...

At 0.5 Hz, Mecp2 null cells exhibited an increase in mean spike slope (mutant, 2.6±0.6 nA/s vs. wildtype, 1.2±0.2 nA/s; t927 = 2.17, P = 0.03), amplitude (mutant, 7.4±0.8 pA vs. wildtype, 4.8±0.5 pA; t1177= 2.68,P = 0.008), and total charge (mutant, 0.22±0.01 pC vs. wildtype, 0.149±0.009 pC; t1201 = 4.60, P = 0.000002), with no change in spike half-width (mutant, 37.3±1.5 ms vs. wildtype, 33.8±1.7 ms; t1203 = 1.54, P = 0.12) compared to wildtype cells. Thus, during transient fusion events, the secretory granules in Mecp2 null cells release more catecholamine (increased total charge) and release faster (increased spike slope) than in wildtype cells.

At 15 Hz, Mecp2 null and wildtype cells exhibited nearly identical spike charge (mutant, 0.329±0.007 pC vs. wildtype, 0.315±0.009 pC; t4439 = 1.21, P = 0.23), indicating that granule catecholamine content and thus maximal quantal size is unaffected by the mutation. However, Mecp2 null cells exhibited significant increases in spike amplitude (mutant, 12.4±0.6 pA vs. wildtype, 8.9±0.4 pA; t5316 = 5.05, P = 0) and mean rate of spike rise (mutant, 4.3±0.3 nA/s vs. wildtype, 2.0±0.1 nA/s; t4587 = 6.77, P = 0), indicating that the rate of catecholamine release per secretory event was significantly higher in mutant cells. In contrast, the mean spike half-width was decreased in Mecp2 null cells (mutant, 29.2±0.7 ms vs. wildtype, 34.8±0.9 ms; t3768 = −4.82, P = 0.0000007), indicating that the granules were emptying faster. Both results indicate a more rapid dilation of the granule fusion pore in Mecp2 null cells compared to wildtype. Moreover, the fact that total spike charge is the same in wildtype and Mecp2 null cells indicates that enhanced catecholamine release at 0.5 Hz is a consequence of the increase in the speed of fusion pore opening (and, perhaps, the size of the fusion pore) rather than an increase in granule catecholamine content. We further investigated this possibility by analyzing spike foot currents. Briefly, a foot current preceding the amperometric spike is broadly interpreted as catecholamine release through the fusion pore prior to granule collapse (Chow et al., 1992). We analyzed foot current duration and charge in cells stimulated at 15 Hz and found both parameters significantly decreased in Mecp2 null mice (t737 = −3.18, P = 0.002 and t641 = −2.55, P = 0.011, respectively; Fig. 4B.v). These data indicate that the fusion pore does indeed dilate faster in null mice compared to wildtype.

Chromaffin granule trafficking to the Readily Releasable Pool (RRP)

We previously found that enhanced catecholamine exocytosis in Mecp2 null adrenal chromaffin cells is associated with an increase in the size of the secretory granule Readily Releasable Pool (RRP) (Wang et al., 2006). To test the possibility that additional mechanisms related to vesicle trafficking to the RRP also influence the Mecp2 null secretory phenotype, we compared the influence of stimulus pulse duration on vesicle fusion and catecholamine secretion in wildtype and mutant cells. In these experiments, isolated chromaffin cells were patch clamped to a holding potential of −80 mV and then stimulated with a series of pulse depolarizations of increasing duration while monitoring cell capacitance (an index of granule fusion) as shown in Figure 5A. At short pulse durations, capacitance changes are limited to fusion of granules in the RRP (Horrigan & Bookman, 1994). However, at long pulse durations, the RRP is consumed and further secretion occurs through additional recruitment and fusion of reserve granules (Voets et al., 1999). Analysis of membrane current recordings from cells stimulated with action potential waveforms showed a typical biphasic shape corresponding to the initial influx of voltage-dependent sodium current followed by voltage-dependent calcium current (Fig. 5A.i). Five milliseconds after the onset of the stimulus the sodium current inactivated, leaving only current due to calcium influx. Change in capacitance (Fig. 5A.ii) was measured by subtracting average capacitance values before and after the pulse. Eleven pulse durations were tested in increasing order (in ms: 5.5, 16.75, 27.5, 52.25, 77, 101.75, 151.25, 228.25, 401.5, 803, 1603.25), and cells were given 45 seconds between pulses to allow full recovery of the RRP (Voets et al., 1999; Chan et al., 2005). Figure 5B shows the results from 12 wildtype cells and 17 mutant cells. For the first seven pulses, Mecp2 null cells consistently showed an increased change in capacitance compared to wildtype, with the largest differences in the plateau region at pulse widths of 52.25 ms (mutant, ΔCm = 36±4 fF vs. wildtype, ΔCm = 24±2 fF; t13 = 2.56, P = 0.024) and 77ms (mutant, ΔCm = 41±5 fF vs. wildtype, ΔCm = 25±2 fF; t14 = 3.03, P = 0.009), where quantal content is limited proportionally to the number of release-ready granules (comprising the RRP). This region of the plot is shown expanded in the inset in Figure 5B. These results indicate a 45–50% increase in the RRP in Mecp2 null cells, consistent with previous results (Wang et al., 2006). However, wildtype and mutant cells showed no difference in cell capacitance in response to longer pulse durations at which recruitment of new granules from the Reserve Pool (RP) to the RRP is required to sustain continued granule fusion. These data indicate, therefore, that enhanced secretion in mutant cells is not due to increased recruitment of granules to the RRP.

Figure 5
Cell capacitance measurements with increasing pulse duration. A) Protocol used to measure change in cell capacitance and total calcium influx. Chromaffin cells were stimulated with a pulse depolarization, evoking the influx of both sodium and calcium ...


The present study reveals a complex phenotype affecting adrenal medullary function in Mecp2 null mice. On the one hand, medullary volume and tissue concentrations of dopamine, norepinephrine and epinephrine are significantly reduced in mutants compared to wildtype controls. However, plasma epinephrine levels are significantly increased, at least under conditions of isoflurane anesthesia. These seemingly paradoxical results may be explained by our finding that isolated Mecp2 null chromaffin cells are hypersecretory, as indicated by 1) enhanced stimulus-secretion coupling, 2) more rapid efflux of catecholamines per granule fusion event, and 3) an increase in the amount of catecholamine released per secretory event under conditions that simulate resting levels of sympathetic activity, i.e., electrical stimulation at 0.5 Hz. Thus, in addition to an increase in the size of the RRP of catecholamine granules (Wang et al., 2006), our data highlight abnormal fusion pore regulation as a previously unrecognized mechanism by which loss of MeCP2 disrupts peripheral catecholamine homeostasis.

Relatively little is known about the genetic control of secretory granule kinetics. It is possible that the secretory granule phenotype of Mecp2 null mice reflects mechanistic alterations in multiple regulatory steps linking chromaffin cell activation to elevated catecholamine release. Indeed, recent studies indicate that, in the nervous system, many hundreds of genes are dysregulated in the absence of MeCP2 (Jordan et al., 2007; Chahrour et al., 2008), and preliminary expression profiling studies in our laboratory indicate that the same is true in the adrenal medulla (unpublished data). One of the most striking features of granule behavior in Mecp2 null cells is the marked increase in the rate of transmitter release, and the more rapid opening of the fusion pore. Thus, at least one consequence of MeCP2 loss appears to be alteration of post-fusion events. The speed of pore opening is subject to regulation by diverse molecules that influence fusion of the granule and plasma membranes, including synaptobrevin 2 (Syb2; Bretou et al., 2008), Munc-18 (Fisher et al., 2001), Regulator of Calcineurin Activity 1 (RCAN1; Keating et al., 2008), Cysteine String Protein (Csp; Graham & Burgoyne, 2000) and Calcium-dependent Activator Protein for Secretion (CAPS; Elhamdani et al., 2000). It is also possible that loss of MeCP2 disrupts expression of proteins comprising the dense core matrix, thereby altering granule swelling and release kinetics (Angleson et al., 1999; Amatore et al., 2000). Studies in progress are attempting to define potential links between MeCP2 signaling and expression of specific molecules involved in regulation of secretory granule fusion kinetics.

We demonstrate here, for the first time, that plasma epinephrine and the epinephrine/norepinephrine ratio are increased in Mecp2 null mice. These results are consistent with our finding that isolated chromaffin cells, devoid of any sympathetic input, are hypersecretory. This hypersecretory phenotype may also alter the sensitivity of Mecp2 null mutants to stress, particularly to isoflurane anesthesia which has been shown to increase circulating catecholamines in human patients (Nishiyama, 2005). It is interesting in this context that mice carrying a truncation mutation in Mecp2 exhibit elevated plasma levels of adrenal corticosteroids in response to stress (McGill et al., 2006). In these animals, elevated secretion was linked to increased expression of corticotrophin releasing hormone in the hypothalamus and, thereby, increased activation of the hypothalamic-pituitary-adrenal axis. Therefore, it is possible that the elevated level of plasma epinephrine that we observe here in Mecp2 null mutants also reflects an exaggerated response to stress resulting from enhanced secretory granule function.

Derangements of autonomic control, and cardiovascular regulation in particular, are prominent features of epinephrine excess. This has been documented particularly in patients with pheochromocytoma (Bravo, 1991; Bianchi et al., 1995; Bravo & Tagle, 2003; Zapanti & Ilias, 2006) or experimental subjects infused with exogenous epinephrine (Johansson et al., 1988; Hansen et al., 1990). The cardiorespiratory sequelae of epinephrine excess exhibit striking overlap with several of the dysautonomic features of RTT. Most notably, common features include cardiac arrhythmias, prolonged corrected Q-T interval, and sudden death (Acampa & Guideri, 2006; Weese-Mayer et al., 2006). Epinephrine excess can also be associated with paroxysmal hypertension, as in some patients with pheochromocytoma, resulting from episodic spikes in adrenal secretion (Bravo, 1991; Bianchi et al., 1995; Bravo & Tagle, 2003; Zapanti & Ilias, 2006). Although resting mean arterial pressure appears to be normal in RTT patients (Julu & Witt Engerstrom, 2005), blood pressure lability over time has not been studied in these patients in detail.

In RTT patients, autonomic dysfunction has been attributed to an apparent imbalance between sympathetic and parasympathetic tone that results in a relative “hyperactivity” of the sympathetic nervous system (Julu et al., 2001; Acampa & Guideri, 2006; Acampa et al., 2008). This imbalance has been suggested to result from brainstem immaturity leading to decreased parasympathetic tone (Julu et al., 1997b, a). Our data suggest an alternative (or complementary) hypothesis, i.e., that elevated catecholamine secretion from the adrenal glands contributes to increased peripheral sympathetic tone in RTT patients. In addition to cardiac dysautonomia, RTT patients exhibit other symptoms consistent with abnormalities in the sympathoadrenal axis, including peripheral vasoconstriction and limb hypothermia (Naidu et al., 1987). Thus, our findings raise the possibility that therapeutic strategies aimed at reducing peripheral epinephrine signaling may be of value for RTT patients. However, any generalized strategy aimed at reducing catecholamine signaling could exacerbate the reduction in norepinephrine observed in the CNS of RTT patients and Mecp2 null mice (for review see Ogier & Katz, 2008). Thus, a more targeted approach, specific for peripheral epinephrine, may be warranted.

Although changes in brain monoamine levels or monoamine synthesizing enzymes have been documented in RTT patients (Riederer et al., 1985; Zoghbi et al., 1985; Brucke et al., 1987; Lekman et al., 1989; Zoghbi et al., 1989; Saito et al., 2001; see, however, Perry et al., 1988; Lekman et al., 1990) and Mecp2 null mice, virtually nothing is known about peripheral catecholamine levels in RTT patients. Our data indicate that defining peripheral catecholamine homeostasis in RTT patients may be critical to understanding autonomic pathophysiology in this disease. More generally, this is to our knowledge the first genetic disease model characterized by enhanced dense core granule function and adrenal hypersecretion of catecholamines.


The authors gratefully acknowledge the excellent technical assistance of Dr. Qifang Wang and thank Batool Akhtar-Zaidi for helpful discussions. Supported by a grant from NINDS to DMK.


bovine serum albumin
high performance liquid chromatography
methyl-CpG-binding protein 2
post-natal day 35
phosphate-buffered saline
reserve pool
readily releasable pool
Rett syndrome
superior cervical ganglion
tyrosine hydroxylase


  • Acampa M, Guideri F. Cardiac disease and Rett syndrome. Arch Dis Child. 2006;91:440–443. [PMC free article] [PubMed]
  • Acampa M, Guideri F, Hayek J, Blardi P, De Lalla A, Zappella M, Auteri A. Sympathetic overactivity and plasma leptin levels in Rett syndrome. Neurosci Lett. 2008;432:69–72. [PubMed]
  • Amatore C, Bouret Y, Travis ER, Wightman RM. Interplay between membrane dynamics, diffusion and swelling pressure governs individual vesicular exocytotic events during release of adrenaline by chromaffin cells. Biochimie. 2000;82:481–496. [PubMed]
  • Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23:185–188. [PubMed]
  • Angleson JK, Cochilla AJ, Kilic G, Nussinovitch I, Betz WJ. Regulation of dense core release from neuroendocrine cells revealed by imaging single exocytic events. Nat Neurosci. 1999;2:440–446. [PubMed]
  • Bianchi AL, Denavit-Saubie M, Champagnat J. Central control of breathing in mammals: neuronal circuitry, membrane properties, and neurotransmitters. Physiol Rev. 1995;75:1–45. [PubMed]
  • Brandt BL, Hagiwara S, Kidokoro Y, Miyazaki S. Action potentials in the rat chromaffin cell and effects of acetylcholine. J Physiol. 1976;263:417–439. [PubMed]
  • Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney Int. 1991;40:544–556. [PubMed]
  • Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003;24:539–553. [PubMed]
  • Bretou M, Anne C, Darchen F. A fast mode of membrane fusion dependent on tight SNARE zippering. J Neurosci. 2008;28:8470–8476. [PubMed]
  • Brucke T, Sofic E, Killian W, Rett A, Riederer P. Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett-syndrome: a postmortem brain study. J Neural Transm. 1987;68:315–324. [PubMed]
  • Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron. 2007;56:422–437. [PubMed]
  • Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008;320:1224–1229. [PMC free article] [PubMed]
  • Chan SA, Smith C. Physiological stimuli evoke two forms of endocytosis in bovine chromaffin cells. J Physiol. 2001;537:871–885. [PubMed]
  • Chan SA, Polo-Parada L, Landmesser LT, Smith C. Adrenal chromaffin cells exhibit impaired granule trafficking in NCAM knockout mice. J Neurophysiol. 2005;94:1037–1047. [PubMed]
  • Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet. 2001;27:327–331. [PubMed]
  • Chow RH, von Ruden L, Neher E. Delay in vesicle fusion revealed by electrochemical monitoring of single secretory events in adrenal chromaffin cells. Nature. 1992;356:60–63. [PubMed]
  • Elhamdani A, Brown ME, Artalejo CR, Palfrey HC. Enhancement of the dense-core vesicle secretory cycle by glucocorticoid differentiation of PC12 cells: characteristics of rapid exocytosis and endocytosis. J Neurosci. 2000;20:2495–2503. [PubMed]
  • Fisher RJ, Pevsner J, Burgoyne RD. Control of fusion pore dynamics during exocytosis by Munc18. Science. 2001;291:875–878. [PubMed]
  • Fulop T, Radabaugh S, Smith C. Activity-dependent differential transmitter release in mouse adrenal chromaffin cells. J Neurosci. 2005;25:7324–7332. [PubMed]
  • Fulop T, Smith C. Physiological stimulation regulates the exocytic mode through calcium activation of protein kinase C in mouse chromaffin cells. Biochem J. 2006;399:111–119. [PubMed]
  • Gomez JF, Brioso MA, Machado JD, Sanchez JL, Borges R. New approaches for analysis of amperometrical recordings. Ann N Y Acad Sci. 2002;971:647–654. [PubMed]
  • Graham ME, Burgoyne RD. Comparison of cysteine string protein (Csp) and mutant alpha-SNAP overexpression reveals a role for csp in late steps of membrane fusion in dense-core granule exocytosis in adrenal chromaffin cells. J Neurosci. 2000;20:1281–1289. [PubMed]
  • Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet. 2001;27:322–326. [PubMed]
  • Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s syndrome: report of 35 cases. Ann Neurol. 1983;14:471–479. [PubMed]
  • Hansen O, Johansson BW, Nilsson-Ehle P. Metabolic, electrocardiographic, and hemodynamic responses to increased circulating adrenaline: effects of selective and nonselective beta adrenoceptor blockade. Angiology. 1990;41:175–188. [PubMed]
  • Horrigan FT, Bookman RJ. Releasable pools and the kinetics of exocytosis in adrenal chromaffin cells. Neuron. 1994;13:1119–1129. [PubMed]
  • Johansson BW, Hansen O, Juul-Moller S, Svensson O. Adrenaline-induced changes in serum electrolytes, ECG, and blood pressure, with Ca-blockade pretreatment. Angiology. 1988;39:345–354. [PubMed]
  • Jordan C, Li HH, Kwan HC, Francke U. Cerebellar gene expression profiles of mouse models for Rett syndrome reveal novel MeCP2 targets. BMC Med Genet. 2007;8:36. [PMC free article] [PubMed]
  • Julu PO, Kerr AM, Hansen S, Apartopoulos F, Jamal GA. Functional evidence of brain stem immaturity in Rett syndrome. Eur Child Adolesc Psychiatry. 1997a;6 Suppl 1:47–54. [PubMed]
  • Julu PO, Kerr AM, Hansen S, Apartopoulos F, Jamal GA. Immaturity of medullary cardiorespiratory neurones leading to inappropriate autonomic reactions as a likely cause of sudden death in Rett’s syndrome. Arch Dis Child. 1997b;77:464–465. [PMC free article] [PubMed]
  • Julu PO, Kerr AM, Apartopoulos F, Al-Rawas S, Engerstrom IW, Engerstrom L, Jamal GA, Hansen S. Characterisation of breathing and associated central autonomic dysfunction in the Rett disorder. Arch Dis Child. 2001;85:29–37. [PMC free article] [PubMed]
  • Julu PO, Witt Engerstrom I. Assessment of the maturity-related brainstem functions reveals the heterogeneous phenotypes and facilitates clinical management of Rett syndrome. Brain Dev. 2005;27 Suppl 1:S43–S53. [PubMed]
  • Keating DJ, Dubach D, Zanin MP, Yu Y, Martin K, Zhao YF, Chen C, Porta S, Arbones ML, Mittaz L, Pritchard MA. DSCR1/RCAN1 regulates vesicle exocytosis and fusion pore kinetics: implications for Down syndrome and Alzheimer’s disease. Hum Mol Genet. 2008;17:1020–1030. [PubMed]
  • Kidokoro Y, Ritchie AK. Chromaffin cell action potentials and their possible role in adrenaline secretion from rat adrenal medulla. J Physiol. 1980;307:199–216. [PubMed]
  • Lekman A, Witt-Engerstrom I, Gottfries J, Hagberg BA, Percy AK, Svennerholm L. Rett syndrome: biogenic amines and metabolites in postmortem brain. Pediatr Neurol. 1989;5:357–362. [PubMed]
  • Lekman A, Witt-Engerstrom I, Holmberg B, Percy A, Svennerholm L, Hagberg B. CSF and urine biogenic amine metabolites in Rett syndrome. Clin Genet. 1990;37:173–178. [PubMed]
  • Malmejac J. Activity of the Adrenal Medulla and Its Regulation. Physiol Rev. 1964;44:186–218. [PubMed]
  • McGill BE, Bundle SF, Yaylaoglu MB, Carson JP, Thaller C, Zoghbi HY. Enhanced anxiety and stress-induced corticosterone release are associated with increased Crh expression in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2006;103:18267–18272. [PubMed]
  • Moretti P, Zoghbi HY. MeCP2 dysfunction in Rett syndrome and related disorders. Curr Opin Genet Dev. 2006;16:276–281. [PubMed]
  • Mullaney BC, Johnston MV, Blue ME. Developmental expression of methyl-CpG binding protein 2 is dynamically regulated in the rodent brain. Neuroscience. 2004;123:939–949. [PubMed]
  • Naidu S, Chatterjee S, Murphy M, Uematsu S, Phillapart M, Moser H. Rett syndrome: new observations. Brain Dev. 1987;9:525–528. [PubMed]
  • Nishiyama T. Hemodynamic and catecholamine response to a rapid increase in isoflurane or sevoflurane concentration during a maintenance phase of anesthesia in humans. J Anesth. 2005;19:213–217. [PubMed]
  • Ogier M, Wang H, Hong E, Wang Q, Greenberg ME, Katz DM. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J Neurosci. 2007;27:10912–10917. [PubMed]
  • Ogier M, Katz DM. Breathing dysfunction in Rett syndrome: understanding epigenetic regulation of the respiratory network. Respir Physiol Neurobiol. 2008;164:55–63. [PMC free article] [PubMed]
  • Pelka GJ, Watson CM, Radziewic T, Hayward M, Lahooti H, Christodoulou J, Tam PP. Mecp2 deficiency is associated with learning and cognitive deficits and altered gene activity in the hippocampal region of mice. Brain. 2006;129:887–898. [PubMed]
  • Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A. 2005;102:2174–2179. [PubMed]
  • Perry TL, Dunn HG, Ho HH, Crichton JU. Cerebrospinal fluid values for monoamine metabolites, gamma-aminobutyric acid, and other amino compounds in Rett syndrome. J Pediatr. 1988;112:234–238. [PubMed]
  • Riederer P, Brucke T, Sofic E, Kienzl E, Schnecker K, Schay V, Kruzik P, Killian W, Rett A. Neurochemical aspects of the Rett syndrome. Brain Dev. 1985;7:351–360. [PubMed]
  • Saito Y, Ito M, Ozawa Y, Matsuishi T, Hamano K, Takashima S. Reduced expression of neuropeptides can be related to respiratory disturbances in Rett syndrome. Brain Dev. 2001;23 Suppl 1:S122–126. [PubMed]
  • Samaco RC, Fryer JD, Ren J, Fyffe S, Chao HT, Sun Y, Greer JJ, Zoghbi HY, Neul JL. A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. Hum Mol Genet. 2008;17:1718–1727. [PMC free article] [PubMed]
  • Shahbazian M, Young J, Yuva-Paylor L, Spencer C, Antalffy B, Noebels J, Armstrong D, Paylor R, Zoghbi H. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron. 2002;35:243–254. [PubMed]
  • Shahbazian MD, Zoghbi HY. Rett syndrome and MeCP2: linking epigenetics and neuronal function. Am J Hum Genet. 2002;71:1259–1272. [PubMed]
  • Smith C, Moser T, Xu T, Neher E. Cytosolic Ca2+ acts by two separate pathways to modulate the supply of release-competent vesicles in chromaffin cells. Neuron. 1998;20:1243–1253. [PubMed]
  • Sugita S. Mechanisms of exocytosis. Acta Physiol (Oxf) 2008;192:185–193. [PubMed]
  • Van den Veyver IB, Zoghbi HY. Genetic basis of Rett syndrome. Ment Retard Dev Disabil Res Rev. 2002;8:82–86. [PubMed]
  • Voets T, Neher E, Moser T. Mechanisms underlying phasic and sustained secretion in chromaffin cells from mouse adrenal slices. Neuron. 1999;23:607–615. [PubMed]
  • Vorsanova SG, Iourov IY, Yurov YB. Neurological, genetic and epigenetic features of Rett syndrome. J Pediatr Neurol. 2004;2:179–190.
  • Wang H, Chan SA, Ogier M, Hellard D, Wang Q, Smith C, Katz DM. Dysregulation of brain-derived neurotrophic factor expression and neurosecretory function in Mecp2 null mice. J Neurosci. 2006;26:10911–10915. [PubMed]
  • Weese-Mayer DE, Lieske SP, Boothby CM, Kenny AS, Bennett HL, Silvestri JM, Ramirez JM. Autonomic nervous system dysregulation: breathing and heart rate perturbation during wakefulness in young girls with Rett syndrome. Pediatr Res. 2006;60:443–449. [PubMed]
  • Zapanti E, Ilias I. Pheochromocytoma: physiopathologic implications and diagnostic evaluation. Ann N Y Acad Sci. 2006;1088:346–360. [PubMed]
  • Zoghbi HY, Percy AK, Glaze DG, Butler IJ, Riccardi VM. Reduction of biogenic amine levels in the Rett syndrome. N Engl J Med. 1985;313:921–924. [PubMed]
  • Zoghbi HY, Milstien S, Butler IJ, Smith EO, Kaufman S, Glaze DG, Percy AK. Cerebrospinal fluid biogenic amines and biopterin in Rett syndrome. Ann Neurol. 1989;25:56–60. [PubMed]